

Supplemental Material for

Interim results from comparison of immune responses elicited by an inactivated and a vectored SARS-CoV-2 vaccine in seronegative and seropositive participants in India

Mangaiarkarasi Asokan^{1,2^^}, Roshni Florina Joan^{3*}, Sudhir Babji^{1*†}, Girish Dayma^{4*}, Prajitha Nitheesh^{2*}, Vinutha Subrahmanyam^{2*}, Archana Pandey^{2*}, Girish Malagi^{5*}, Pooja Arya^{5*}, Vibhuti Mahajan^{5*}, Jayateerth Bhavikatti^{6*}, Ketakee Pawar^{6*}, Aishwarya Thorat^{6*}, Priyanki Shah^{7*}, Ramakrishna B Goud^{8*}, Bishnudeo Roy^{9*}, Shon Rajukutty^{3#}, Sushil Immanuel^{1#}, Dhiraj Agarwal^{4#}, Sankhanil Saha^{2#}, Akshatha S^{2#}, Patricia Panikulam^{2#}, Rajeshwari Shome^{2#}, Shah-E-Jahan Gulzar^{2#}, Anusmriti U Sharma^{10#}, Ajinkya Naik^{6#}, Shruti Talashi^{6#}, Madhuri Belekar^{6#}, Ritu Yadav^{6#}, Poornima Khude^{7#}, Mamatha V^{8#}, Sudarshan S^{8#}, Urmila Deshmukh^{9#}, Chinmayee Bhise^{9#}, Manjiri Joshi^{9#}, Leeberk Raja Inbaraj^{3**}, Sindhulina Chandrasingh^{3**}, Aurnab Ghose^{11**}, Colin Jamora^{10**}, Anandi S Karumbati^{10**}, Varadharajan Sundaramurthy^{2**}, Avita Johnson^{8**}, Naveen Ramesh^{8**}, Nirutha Chetan^{8**}, Chaitra Parthiban^{8**}, Asma Ahmed^{8**}, Srabanti Rakshit^{8**}, Vasista Adiga^{8**}, George D'souza^{8**}, Vinay Rale^{9**}, Carolin Elizabeth George^{3^}, Jacob John^{2^}, Anand Kawade^{4^}, Akanksha Chaturvedi^{5^}, Anu Raghunathan^{6^}, Mary Dias^{8^}, Anand Bhosale^{9^}, Padinjat Raghu², Shashidhara LS⁷, Annapurna Vyakarnam^{8,12}, Vineeta Bal¹¹, Gagandeep Kang¹, Satyajit Mayor^{2^^}

*, #, ** These authors contributed equally

† Deceased

^These are senior authors from their institutions

^^Co-corresponding authors

1 Christian Medical College, Vellore, Tamil Nadu, India

2 National Centre for Biological Sciences, Bengaluru, Karnataka, India

3 Bangalore Baptist Hospital, Bengaluru, Karnataka, India

4 King Edward Memorial Hospital and Research Centre, Pune, Maharashtra, India

5 National Centre for Cell Sciences, Pune, Maharashtra, India

6 National Chemical Laboratory, Pune, Maharashtra, India

7 Pune Knowledge Cluster, Pune, Maharashtra, India

8 St. John's Research Institute, Bengaluru, Karnataka, India

9 Symbiosis University Hospital and Research Centre, Symbiosis Medical College for Women, Symbiosis School of Biological Sciences, Symbiosis International (Deemed University), Pune, Maharashtra, India

10 Institute for Stem Cell Science and Regenerative Medicine, Bengaluru, Karnataka, India


11 Indian Institute of Science Education and Research-Pune, Pune, Maharashtra, India

12 King's College, London, United Kingdom


	Overall cohort	
	Seronegative	Seropositive
Covaxin		
Week 0 vs Week 4	0.0002	0.0037
Week 0 vs Week 6	<0.0001	<0.0001
Week 4 vs Week 6	0.0009	0.1280
Covishield		
Week 0 vs Week 4	<0.0001	<0.0001
Week 0 vs Week 14	<0.0001	<0.0001
Week 4 vs Week 14	0.0001	<0.0001
BBH		
Covaxin		
Week 0 vs Week 4	0.1283	0.1996
Week 0 vs Week 6	0.0604	<0.0001
Week 4 vs Week 6	0.2133	<0.0001
Covishield		
Week 0 vs Week 4	0.0007	<0.0001
Week 0 vs Week 14	<0.0001	<0.0001
Week 4 vs Week 14	0.0002	0.0030
KEM		
Covaxin		
Week 0 vs Week 4	0.0059	<0.0001
Week 0 vs Week 6	0.0015	<0.0001
Week 4 vs Week 6	0.0054	0.0022
Covishield		
Week 0 vs Week 4	0.0081	<0.0001
Week 0 vs Week 14	<0.0001	<0.0001
Week 4 vs Week 14	0.3420	<0.0001
SUHRC		
Covaxin		
Week 0 vs Week 4	0.3932	0.0101
Week 0 vs Week 6	0.0004	<0.0001
Week 4 vs Week 6	0.0018	0.0012
Covishield		
Week 0 vs Week 4	0.0051	<0.0001
Week 0 vs Week 14	<0.0001	<0.0001
Week 4 vs Week 14	0.9652	0.1407
SJRI		
Covaxin		
Week 0 vs Week 4	0.0780	0.2281
Week 0 vs Week 6	0.0696	0.0565
Week 4 vs Week 6	0.5751	0.6767
Covishield		
Week 0 vs Week 4	0.0117	<0.0001
Week 0 vs Week 14	<0.0001	<0.0001
Week 4 vs Week 14	0.1217	0.0181

Supplementary table 2 Change in antibody titers over time within each study group in each cohort Data are p-values of two-way ANOVA with Tukey's correction to compare differences over time in each cohort within each study group.

Seronegative Covaxin







Seronegative Covishield







- Double responders
- Non-responders
- ▲ First dose responders
- ◆ Second dose responders
- Reverted


Seronegative Covaxin




Seronegative Covishield




Supplementary Figure 1B)




Seropositive Covaxin



Seropositive Covishield



Supplementary figure 1 Classification of study participants based on antibody trajectories following vaccination A) Seronegatives B) Seropositives. Arrowheads indicate the time of vaccination




B)

Covaxin	Seronegative					Seropositive				
	Week 0	Week 4	Week 6	Week 12	Week 14	Week 0	Week 4	Week 6	Week 12	Week 14
BBH vs. KEM	0.4247	0.4135	0.4141			0.9926	0.5642	0.8504		
BBH vs. SUHRC	0.8249	>0.9999	0.3151			0.0476	0.0422	0.1298		
BBH vs. SJRI	0.4136	0.1881	0.2646			>0.9999	0.3516	0.1421		
KEM vs. SUHRC	0.9996	0.5519	0.9914			0.0540	0.0022	0.0276		
KEM vs. SJRI	0.9740	0.3481	0.5631			0.9987	0.4378	0.2217		
SUHRC vs. SJRI	0.9980	0.1932	0.4845			0.6186	0.2486	0.0459		
Covishield										
BBH vs. KEM	0.1510	0.4588		0.0501	0.9941	0.0036	0.9985		0.8878	0.8025
BBH vs. SUHRC	0.0002	0.1040		0.0164	0.8031	0.0199	0.0706		0.6310	0.9317
BBH vs. SJRI	0.0381	0.5972		0.0011	0.9955	>0.9999	0.4477		0.9925	0.8344
KEM vs. SUHRC	0.1467	0.6617		0.4613	0.9027	0.8693	0.0235		0.8948	0.9935
KEM vs. SJRI	0.9203	0.9934		0.0181	>0.9999	0.2299	0.3750		0.8022	>0.9999
SUHRC vs. SJRI	0.4730	0.5103		0.2356	0.8804	0.3486	0.7973		0.5703	0.9923


Supplementary Figure 2. Change in antibody titers within each study group across cohorts. Antibody responses against ancestral spike measured on the Diasorin TrimericS platform for per-protocol population across each site. Participants were classified as either seronegative or seropositive at baseline using the assay cut-off of 33.8 BAU/ml (horizontal dotted line). Stars within each graph indicate timepoints where sampling in greater than 25% of the population from the cohort was performed during the Omicron wave in January and February 2022. Colors of the stars indicate the cohort. Statistical comparisons between cohorts at each timepoint were performed using a two-way ANOVA with Tukey's correction. B) summary of p-values

Supplementary Figure 3A)





Uninfected cells Infected cells (0.01 MOI)



Infected cells + test sample at indicated dilution



Supplementary Figure 3B)





Supplementary Figure 3C)



Seronegative Covaxin

Seronegative Covishield



Spike (TrimericS)



Spike (MSD)



Nucleocapsid (MSD)





Supplementary Figure 3D)



Seropositive Covaxin

Seropositive Covishield



Spike (TrimericS)



Spike (MSD)





Nucleocapsid (MSD)



Supplementary figure 3 A) Representative light microscope images showing determination of neutralizing titers. The highlighted image (1:40) shows the highest dilution of plasma at which there is complete rescue of virus-induced cytopathic effects. B) Pearson correlation between neutralization titers against authentic virus and either anti-spike binding IgG or percent inhibition of ACE-2 binding to ancestral spike protein. C,D) Binding antibody titers in participants who were included for neutralization assay from seronegative and seropositive groups respectively.

Supplementary Figure 4A)



Related to figure 3





Seronegative Covaxin

Seronegative Covishield



Spike (Trimeric_S)



Spike (MSD)





Nucleocapsid (MSD)





Seropositive Covaxin

Seropositive Covishield



Spike (TrimericS)





Spike (MSD)





Nucleocapsid (MSD)





Supplementary figure 4 A) Representative gating strategy for flow cytometry-based quantification of antigen-specific T cells expressing IFN γ , IL2 and/or TNF. B,C) Antibody responses against spike and nucleocapsid proteins in the seronegative and seropositive participants included in the ICS assay.





PHA



N+M











Spike



Supplementary Figure 5C)


Related to figure 3



Supplementary Figure 5 T cell responses prior to vaccination in seronegative versus seropositive participants. A) T cell responses against a pool of peptides derived from either ancestral spike or a mixture N and M or control PHA measured by ICS in one of the cohorts. Background responses from an unstimulated control were subtracted. Participants were classified as either seronegative (n=25) or seropositive (n=44) against SARS-CoV-2 spike at baseline using the MSD assay. Solid horizontal line (red) indicates the group median. Differences between seronegatives and seropositives were assessed using Kruskal-Wallis test with Dunn's correction. B) Antigen-specific responses are shown for each of the indicated cytokines. Bar heights represent the group median. Differences between seronegatives and seropositives were assessed using Kruskal-Wallis test with Dunn's correction. C) Pearson correlation between antibody titers and spike-specific or nucleocapsid-specific CD4 T cells prior to vaccination


Supplementary figure 6A)

TrimericS-based classification





Supplementary figure 6B)

MSD-based classification



Spike



Covaxin Covishield



Week 0 6 14 0 6 14 0 6 14 0 6 14

N+M



Covaxin Covishield



Week 0 6 14 0 6 14 0 6 14 0 6 14

PHA

Covaxin Covishield




Week 0 6 14 0 6 14 0 6 14 0 6 14

Supplementary Figure 6 A, B) Spike-specific T-cell responses among participants classified as either responders or non-responders based on antibody titers measured on A) TrimericS or B) MSD platform. Responders were classified as those whose post-vaccination antibody titers were greater than either 33.8 BAU/ml on Trimeric S or 1960 AU/ml (MSD units). Statistical comparisons were made using Kruskal-Wallis test with Dunn's correction. Bar heights represent group median

C) T-cell responses shown against individual cytokines pre- and post-vaccination against the indicated antigens (either spike, mixture of N and M or PHA). Statistical comparisons were made using Kruskal-Wallis test with Dunn's correction. Bar heights represent group median


Supplementary figure 7A)

TrimericS-based classification




Supplementary figure 7B)

MSD-based classification



Supplementary figure 7C)



Supplementary Figure 7

A, B) Spike-specific T-cell responses among participants classified as either responders or non-responders based on antibody titers measured on A) TrimericS or B) MSD platform. Responders were classified as those whose post-vaccination antibody titers were atleast 2-fold greater than at baseline. Statistical comparisons were made using Kruskal-Wallis test with Dunn's correction. Bar heights represent group median

C) T-cell responses shown against individual cytokines pre- and post-vaccination against the indicated antigens (either spike, mixture of N and M or PHA). Statistical comparisons were made using Kruskal-Wallis test with Dunn's correction. Bar heights represent group median